A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer

• Главные авторы: Thomas G. Frazier (Автор), Kevin R. Fox (Автор), J. Stanley Smith (Автор), Christine Laronga (Автор), Anita McSwain (Автор), Devchand Paul (Автор), Michael Schultz (Автор), Joseph Stilwill (Автор), Christine Teal (Автор), Tracey Weisberg (Автор), Judith F. Vacchino (Автор), Amy P. Sing (Автор), Dasha Cherepanov (Автор), Wendy Hsiao (Автор), Eunice Chang (Автор), Michael S. Broder (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2015-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multicent...